Aspireo Pharmaceuticals Overview

  • Founded
  • 2010

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $33.2M

Aspireo Pharmaceuticals General Information


Developer of somatostatin analogs for the treatment of diseases resulting from hormone-active tumors. The company offers Somatoprim, a novel somatostatin analog used to treat patients with disorders such as diabetic retinopathy and cushings diseases.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Primary Office
  • PO Box 880
  • Ra'anana 43108
  • Israel

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aspireo Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 30-Jun-2015 $33.2M 000.00 Completed Generating Revenue
1. Early Stage VC 01-Dec-2010 Completed Startup
To view Aspireo Pharmaceuticals’s complete valuation and funding history, request access »

Aspireo Pharmaceuticals Executive Team (4)

Name Title Board Seat Contact Info
Carsten Dehning Chief Executive Officer & Chairman
Ian Hunneyball Ph.D Chief Scientific Officer & Consultant
Shaun Marcus Chief Financial Officer & Director
You’re viewing 3 of 4 executive team members. Get the full list »

Aspireo Pharmaceuticals Board Members (2)

Name Representing Role Since
Carsten Dehning Aspireo Pharmaceuticals Chief Executive Officer & Chairman 000 0000
You’re viewing 1 of 2 board members. Get the full list »

Aspireo Pharmaceuticals Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
TVM Capital Life Science Venture Capital Minority 000 0000 000000 0
To view Aspireo Pharmaceuticals’s complete investors history, request access »